Menu
Search
|

Menu

Close
X

Sangamo Therapeutics Inc SGMO.OQ (NASDAQ Stock Exchange Global Select Market)

24.95 USD
-0.45 (-1.77%)
As of 2:29 AM IST
chart
Previous Close 25.40
Open 25.65
Volume 782,116
3m Avg Volume 393,880
Today’s High 26.80
Today’s Low 24.70
52 Week High 27.50
52 Week Low 3.65
Shares Outstanding (mil) 83.61
Market Capitalization (mil) 1,333.59
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.86 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
37
FY16
19
FY15
40
EPS (USD)
FY17
-0.708
FY16
-1.016
FY15
-0.583
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
56.94
5.77
Price to Book (MRQ)
vs sector
6.86
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
2.00
16.52
LT Debt to Equity (MRQ)
vs sector
2.00
12.22
Return on Investment (TTM)
vs sector
-28.31
14.43
Return on Equity (TTM)
vs sector
-32.60
16.13

EXECUTIVE LEADERSHIP

Alexander Macrae
President, Chief Executive Officer, Director, Since 2016
Salary: $350,000.00
Bonus: $347,000.00
Kathy Yi
Chief Financial Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
Heather Turner
Senior Vice President, General Counsel, Since 2018
Salary: --
Bonus: --
Edward Conner
Senior Vice President and Chief Medical Officer, Since 2016
Salary: $34,848.00
Bonus: $100,000.00
Curt Herberts
Senior Vice President and Chief Business Officer, Since 2016
Salary: $289,375.00
Bonus: $72,886.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

501 Canal Blvd
RICHMOND   CA   94804-3559

Phone: +1510.9706000

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

SPONSORED STORIES